LONDON, Jan 24 (Reuters) - Europe's drug watchdog on Thursday said it would make no changes to the label of Merck & Co's MRK.N cervical cancer treatment Gardasil, saying the benefits outweigh any risks.
The European Medicines Agency said it had received reports of the deaths of two women in the European Union who had previously used the vaccine but no link with the drug has been established.
Gardasil is approved in the European Union for the prevention of cervical cancer and other diseases caused by the human papilloma virus. An estimated 1.5 million women have been vaccinated with the drug in Europe, the agency said. (Reporting by Michael Kahn and Marc Jones; Editing by Rory Channing)
Our Standards: The Thomson Reuters Trust Principles.